SS&C Technologies projects 5% organic growth for 2025, highlights $6.2B revenue target
Q4 2024 Management View CEO Bill Stone reported record financial results for Q4 2024, including adjusted revenue of $1.531 billion, up 8.4%, and adjusted diluted EPS of $1.58, marking a 25.4% increase ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...